A new study by LMU and Helmholtz Munich shows how pathogens control changes in their cell surface to evade the immune system.

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

Among men who had persistent prostate-specific antigen (PSA) after radical prostatectomy (RP), a higher preoperative PSA ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

Investigators assess the impact of increasing persistent PSA levels on prostate cancer–specific mortality and all-cause ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

The immune system responds to an infection by producing antibodies that recognize and bind to the cell surface of the ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.